EFFECTS OF PLATELET-RICH PLASMA INJECTIONS ON OSTEOARTHRITIC PATIENTS

Objective: Various treatment options are available for knee osteoarthritis such as medical treatment with NSAID, conservative management with platelet-rich plasma (PRP) and corticosteroids. We have done this prospective study to know the use and safety of platelet-rich plasma (PRP) injections in knee osteoarthritis (KOA) patients. We know platelet-rich plasma (PRP) clinical and functional outcome in knee osteoarthritis (KOA) by doing this study and using the available literature. Methods: This prospective study consisted of a total number of 96 patients suffering from knee osteoarthritis. Both males and females are included. Intra-articular injection of platelet-rich plasma (PRP) was given in sterile conditions and clinical and functional outcomes were analyzed with Western Ontario and McMaster University Arthritis Index (WOMAC), Visual Analogic Scale (VAS), and Knee Society score (KSS). This study is done in a tertiary care institute during the study period. Results: Most patients were females aged>40 y with knee osteoarthritis. The injections of platelet-rich plasma (PRP) showed results at three, six and twelve months follow-up showed significantly reduced WOMAC scores, Visual Analogic Scale (VAS) and Knee Society score (KSS). No complications were observed during the follow-up period. Conclusion: The results confirm the efficacy of the PRP injections on Knee osteoarthritis, suggesting that decreasing pain was obtained one month after injection, with the best results observed after 12 mo; however, a more extensive study group. Follow-up is required for a prolonged period to assess the efficacy of PRP injection.


INTRODUCTION
This prospective study aimed to know the use and safety of plateletrich plasma (PRP) injections in knee osteoarthritis (KOA) patients.Primary knee osteoarthritis (O.A.) continues to be a hard-to-control degenerative disease.With the increase in average life expectancy and the prevalence of obesity, O. A. is creating a rising economic and physical burden [1].Knee osteoarthritis (O.A.) is a chronic musculoskeletal condition that can eventually require surgical in knee osteoarthritis (O.A.) intervention.Thus patients continue to search for potential non operative therapies, such as platelet-rich plasma (PRP) injections into the affected knee [2].According to Jayaram et al., platelet-rich plasma (PRP) is an emergent therapeutic approach for treating O. A.; however, clinical evidence is still needed for its effectiveness, and its mechanisms of action are indeterminate [3].Despite promising outcomes reported about platelet-rich plasma (PRP) utilization in knee O. A., crucial issues such as conclusive evidence about its effectiveness, standard dose, and good.Preparation techniques still need to be discovered [4].Contemporary guidelines advise both non-drug (such as exercise) and drug treatments, such as oral non-steroidal anti-inflammatory drugs (NSAIDs) [5].Repeated injections are related to augmented cartilage Loss [6].An autologous blood product containing various growth factors (G.F. s), cytokines, and platelet-rich plasma (PRP) is given intra-articular has shown promising results in achieving this goal and evaluating the effects of Intra articular platelet-rich plasma (PRP) injections on symptoms and joint structure in patients with symptomatic mild to moderate Osteoarthritis from January 2022 to January 2023.Patients received three consecutive platelet-rich plasma (PRP) injections and Western Ontario and McMaster University Arthritis Index (WOMAC), Visual Analogic Scale (VAS), Knee society score (KSS), Knee society score (KSS) are evaluated before giving platelet-rich plasma (PRP) injection (T0), three months (T1), six months (T2), and twelve months (T3) after the treatment.All patients underwent baseline, and at 12 mo, follow-up, MRI and X-ray evaluation was done.

MATERIALS AND METHODS
It is a prospective observational study in the Department of Orthopedics, Kurnool Medical College.Based on the data collected from the registers from January 2022 to January 2023, the data includes the demographic characteristics (i.e., Age and Gender of the patients).This study was conducted after getting proper consent from all the patients involved.This study was conducted after taking ethical committee approval from Kurnool medical college with approval no 0122/KMC/2022.
All tests were performed in the same place, and the same researchers (two orthopedic surgeons with more than ten years of experience in knee surgery) tested all patients.The evaluation times were T0 (recruitment), T1 (three months after the last injection), T2 (six months after the last injection), and T3 (twelve months after the previous injection).Their MRI and X-ray images at baseline and 12 mo were analyzed and included in this study.

Prp preparation
In the treatment, the procedure was as follows.
A 20 cc syringe with two cc of ADA, and 18 cc venous blood was drawn.Blood was injected into the centrifuge vial through the upper port.After 1 st centrifugation in the "REMI" platelet-rich plasma (PRP) centrifuge, the height was adjusted, pulling the knob up and down.Plasma and the RBC layer were blocked.After the 2nd centrifugation, the upper silicone lid was opened, and a pipette was extracted from the platelet-rich plasma (PRP).A leukocyte filter was then used, and platelet-rich plasma (PRP) activation was done by adding 10% calcium chloride.Platelet-rich plasma (PRP) was injected with the help of a 10 ml syringe.Finally, the platelet concentrate was drawn.The platelet-rich plasma (PRP) was divided into two disposable syringes.One syringe was sent for analysis of platelet concentration, and the second part was used for intraarticular injection in patients within two hours of preparation.
The first injection was given under aseptic conditions-10 ml of platelet-rich plasma (PRP) through the anterolateral approach with a 22-gauge needle was given into the knee joint.Moving the knee allows the platelet-rich plasma (PRP) to spread in the knee joint.The knee was kept in extension for 25 min.After injection, some patients who developed complications like sweating, dizziness, and nausea were observed and discharged when fully recovered.All patients were followed up at three months, six months, and one year.Western Ontario and McMaster University Arthritis Index (WOMAC) scoring and Visual Analogue Scale (VAS) for pain before starting the treatment and then at six weeks, three months, six months, and one year of treatment.

RESULTS
The current study recruited one hundred patients (38 males and 62 females) males affected by knee osteoarthritis (O.A.).The mean age of the knee osteoarthritis (O.A.) patient was 59, with the patients' age range between 40 and 81 y.Out of these 100 patients, some patients were lost to follow-up.Out of 96 finally analyzed patients, 60 were female and 36 were male and received platelet-rich plasma (PRP) injections.No complications were observed during the follow-up period.

Womac pain scale
It is a questionnaire consisting of 24 items divided into three subscales.
Pain (5 items): walking, using stairs, in bed, sitting or lying, and standing upright.
Stiffness (2 items): after first waking and during the day

Physical function (17 items)
Using stairs, standing, bending, walking, getting in or out of a car, shopping, putting on/taking off socks.The questions are scored on a scale from zero to four, corresponding to 0-none, 1-mild, 2-moderate, 3-severe; 4-extreme.The scores for each sub-scale are summed up with a score range of 0-20 for pain, 0-8 for stiffness, and 0-68 for function.Higher WOMAC scores indicate worse pain, stiffness and functional decrease in activity.The WOMAC functional limitations value demonstrated a statistically significant reduction betweenT0 and T1, T1-T2, T2-T3, and T0 and T3.The WOMAC pain value showed statistically significant reduction between T0-T1, between T1-T2, between T2-T3 and, and between T0-T3.The WOMAC total value showed a statistically significant reduction between T1 and T2, T2 and T3, and T0 and T3.The WOMAC stiffness value showed a statistically significant reduction between T0 and T1 and T2 and T3.However, the study by Benn ell et al. showed that among patients with symptomatic mild-to-moderate radiographic knee osteoarthritis (O.A.), intra-articular injection of platelet-rich plasma (PRP) did not result in a significant difference in symptoms at 12 mo compared with saline injection (placebo) [11].Compared with other studies in our study, we found that platelet-rich plasma (PRP) infiltrations represent a beneficial conservative treatment to reduce pain and improve functional scores at the midterm 12 mo follow-up.Positive effects were shown on patients with decreasing pain, as indicated by the WOMAC pain index, and KSS patients with reduced pain, as noted in the WOMAC pain index, KSS index, and Visual analogue scale (VAS), physical function was improved, even if there was no statistical evidence comparing the KSS Score at three-month, six-month, and 12 mo follow-ups.,However, In our study, there need to be more statistical differences in the Knee Score part of KSS that refers to flexion contracture, extension lag, alignment, anteroposterior and mediolateral stability.This aspect has never been pointed out by other authors, who directed only to the total KSS score, suggesting that further study is required to highlight the role of the pain score on the total KSS score.Most studies do not show an improvement in X-rays and MRI, which aligns with our results.However long term follows up with increase in sample size of patients is needed to know the clinical efficacy of platelet rich plasma (PRP).